China's CARsgen Joins European Plan for Tumor Therapy

---

Researched by Industrial Info Resources (Sugar Land, Texas)--Pharmaceutical company CARsgen Therapeutics Holdings Limited (Xuhui, China) recently joined European Medicines Agency's (EMA) PRIME (Priority Medicine) plan for its CAR-T Therapy product CT041, which is used to treat solid tumors.

Industrial Info is tracking 10 active gene and cell therapy projects in China, worth more than $725 million in total. The company with the largest expenditure on gene and cell therapy plant construction is Tonghua Anruite Biopharmaceutical Company Limited, which has planned more than $237.74 million, followed by Shanghai Shangyao Biopharma Company Limited, with more than $177.2 million.

Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list of related projects.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.